Takeda Pharmaceutical Company Limited

Victoria Feher

Zhe Nie

Benjamin Jones

Betty Lam

Qing Dong

Christopher Ronald Smith

Yasuyoshi Arikawa

Masashi Takahashi

Jeffrey Alan Stafford

Stephen W Kaldor

Sheldon Cao

Andre A Kiryanov

Yan Liu

Takashi Ichikawa

Chrisopher McBride

Srinivasa Ready Natala

Disclosed are compounds of Formula 1, and pharmaceutically acceptable salts thereof, wherein G, L, L, R, R, R, and Rare defined in the specification. This disclosure also relates to materials and methods for preparing compounds of Formula 1, pharmaceutical compositions containing them, and their use for treating disorders, diseases, and conditions involving the immune system and inflammation, including rheumatoid arthritis, hematological malignancies, epithelial cancers (i.e., carcinomas), and other disorders, diseases, and conditions for which inhibition of SYK is indicated.

Fused heteroaromatic pyrrolidinones as SYK inhibitors

Fused heteroaromatic pyrrolidinones

Compounds of the following formula are provided for use with kinases: wherein the variables are as defined herein. Also provided are pharmaceutical compositions, kits and articles of manufacture comprising such compounds; methods and intermediates useful for making the compounds; and methods of using said compounds.

Polo-like kinase inhibitors

Growing community of inventors

San Diego, CA, United States of America

Victoria Feher